The GSTM1null (deletion) and MGMT84 rs12917 (Phe/Phe) haplotype are associated with bulky DNA adduct levels in human leukocytes

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 758, Issue 1-2, 2013, Pages 62-68

  Molina, Edith ^a   Pérez Morales, Rebeca ^b   Rubio, Julieta ^a   Petrosyan, Pavel ^a   Cadena, Leticia Hernández ^c   Arlt, Volker M ^d   Phillips, David H ^d   Gonsebatt, María E ^a  

^a UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^b UNIVERSIDAD JUÁREZ DEL ESTADO DE DURANGO   (Mexico)

^c INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^d KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Gene interaction32P postlabeling; GSTM1; MGMT; Risk polymorphisms

Indexed keywords

CIGARETTE SMOKE; CYTOCHROME P450 1A1; DNA; EPOXIDE HYDROLASE; GLUTATHIONE TRANSFERASE M1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE 84; NITROSAMINE; NUCLEOTIDE; PHENYLALANINE; PHOSPHORUS 32; POLYCYCLIC AROMATIC HYDROCARBON; PROTEIN P53; TOBACCO SPECIFIC NITROSAMINE; UNCLASSIFIED DRUG; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ADULT; ARTICLE; CELL CYCLE; CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; FEMALE; GENE DELETION; GENE EXPRESSION; GENETIC ANALYSIS; GENOTYPE; HAPLOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; ISOTOPE LABELING; LEUKOCYTE; MALE; METABOLISM; MEXICO; NULL ALLELE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING; SMOKING HABIT; WILD TYPE;

NICOTIANA TABACUM;

EID: 84887998560     PISSN: 13835718     EISSN: 18793592     Source Type: Journal    
DOI: 10.1016/j.mrgentox.2013.09.007     Document Type: Article

References (64)

1. International Agency for Research on Cancer (IARC) Monographs on the Evaluation of Carcinogenic Risks to Humans 2004, vol. 83. IARC, Lyon, France.
2. Environmental Protection Agency (EPA), 2006. Integrated Risk Information System (IRIS). Available from URL: (accessed 26.02.10). http://www.epa.gov/ncea/iris.
3. Kim J.H., Sherman M.E., Curriero F.C., Guengerich F.P., Strickland P.T., Sutter T.R. Expression of cytochromes P450 1A1 and 1B1 in human lung from smokers, non-smokers, and ex-smoker. Toxicol. Appl. Pharmacol. 2004, 99:210-219.
4. Nilson R. The molecular basis for induction of human cancers by tobacco specific nitrosamines. Regul. Toxicol. Pharmacol. 2011, 60:268-280.
5. 32P-postlabeling and use of knockout mice for Ah receptor-independent mechanisms of metabolic activation in vivo. Int. J. Cancer 2003, 103:5-11.
6. Pelkonen O., Nebert D.W. Metabolism of polycyclic aromatic hydrocarbons: etiologic role in carcinogenesis. Pharmacol. Rev. 1982, 34:189-222.
7. Kaina B., Christmann M., Naumann S., Roos W.P. MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst.) 2007, 6:1079-1099.
8. 6-methylguanine-DNA-methyltransferase (MGMT) gene increase human sensitivity to the genotoxic effects of the tobacco-specific nitrosamine carcinogen NNK. Pharmacogenet. Genom. 2005, 15:571-578.
9. 6-methylguanine. Mutagenesis 2002, 17:483-487.
10. 6-methylguanine-DNA-methyltransferase (MGMT) gene is associated with increased hypoxanthine phosphoribosyltransferase (HPRT) mutant frequency in lymphocytes of tobacco smokers. Pharmacogenet. Genom. 2007, 17:743-753.
11. Hang B. Formation and repair of tobacco carcinogen-derived bulky DNA adducts. J. Nucleic Acids 2010, December. (Article ID 709521).
12. Rossner P., Svecova V., Schmuczerova J., Milcova A., Tabashidze N., Topinka J., Pastorkova A., Sram R.J. Analysis of biomarkers in a Czech population exposed to heavy air pollution. Part I: Bulky DNA adducts. Mutagenesis 2013, 28:89-95.
13. Povey A.C., Margison G.P., Santibáñez-Koref M.F. Lung cancer risk and variation in MGMT activity and sequence. DNA Repair (Amst.) 2007, 6:1134-1144.
14. 6-methylguanine-DNA methyltransferase with risk of lung cancer in non-hispanic whites. Cancer Epidemiol. Biomarkers Prev. 2006, 15:2364-2369.
15. Graziano C., Comin C.E., Crisci C., Novelli L., Politi L., Messerini L., Andreani M., Porfirio B. Functional polymorphisms of the microsomal epoxide hydrolase gene: a reappraisal on an early-onset lung cancer patients series. Lung Cancer 2009, 63:187-193.
16. Wong J.M., Okey A.B., Harper P.A. Human aryl hydrocarbon receptor polymorphisms that result in loss of CYP1A1 induction. Biochem. Biophys. Res. Commun. 2001, 288:990-996.
17. Petersen D., McKinney C., Ikeya K., Smith H., Bale A., Wesley O., Nebert D. Human CYP1A1 gene: cosegregation of enzyme inducibility phenotype and an rflp. Am. J. Hum. Genet. 1991, 48:720-725.
18. Schwarz D., Kisselev P., Chernogolov A., Schunck W., Roots I. Human CYP1A1 variants lead to differential eicosapentaenoic acid metabolite patterns. Biochem. Biophys. Res. Commun. 2005, 336:779-783.
19. Gallegos M.P., Figuera L.E., Troyo R., Morgan G., Puebla A.M., Flores M.R., Zuñiga G.M. CYP1A1 *2B and *4 polymorphisms are associated with lung cancer susceptibility in Mexican patients. Int. J. Biol. Markers 2008, 23:24-30.
20. Lodovici M., Luceri C., Guglielmi F., Bacci C., Akpan V., Fonnesu M.L., Boddi V., Dolara P. Benzo(a)pyrene diolepoxide (BPDE)-DNA adduct levels in leukocytes of smokers in relation to polymorphism of CYP1A1, GSTM1, GSTP1, GSTT1, and mEH. Cancer Epidemiol. Biomarkers Prev. 2004, 13:1342-1348.
21. Rojas M., Cascorbi I., Alexandrov K., Kriek E., Auburtin G., Mayer L., Kopp-Schneider A., Roots I., Bartsch H. Modulation of benzo[a]pyrene diolepoxide-DNA adduct levels in human white blood cells by CYP1A1, GSTM1 and GSTT1 polymorphism. Carcinogenesis 2000, 21:35-41.
22. Pavanello S., Pulliero A., Siwinska E., Mielzynska D., Clonfero E. Reduced nucleotide excision repair and GSTM1-null genotypes influence anti-B[a]PDE-DNA adduct levels in mononuclear white blood cells of highly PAH-exposed coke oven workers. Carcinogenesis 2005, 26:169-175.
23. Ryberg D., Skaug V., Hewer A., Phillips D.H., Harries L.W., Wolf C.R., Ogreid D., Ulvik A., Vu P., Haugen A. Genotypes of glutathione transferase M1 and P1 and their significance for lung DNA adduct levels and cancer risk. Carcinogenesis 1997, 18:1285-1289.
24. Zienolddiny S., Campa D., Lind H., Ryberg D., Skaug V., Stangeland L., Phillips D.H., Canzian F., Haugen A. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006, 27:560-567.
25. Lunn R.M., Helzlsouer K.J., Parshad R., Umbach D.M., Harris E.L., Sanford K.K., Bell D.A. XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 2000, 21:551-555.
26. Zhao H., Wang L.E., Li D., Chamberlain R.M., Sturgis E.M., Wei Q. Genotypes and haplotypes of ERCC1 and ERCC2/XPD genes predict levels of benzo[a]pyrene diol epoxide-induced DNA adducts in cultured primary lymphocytes from healthy individuals: a genotype-phenotype correlation analysis. Carcinogenesis 2008, 29:1560-1566.
27. Irarrazabal C.E., Rojas C., Aracena R., Márquez C., Gil L. Chilean pilot study on the risk of lung cancer associated with codon 72 polymorphism in the gene of protein p53. Toxicol. Lett. 2003, 144:69-76.
28. Poirier M. Chemical-induced DNA damage and human cancer risk. Nature Aug 4 2004, 630-637. (Review).
29. 32P-postlabeling assay for DNA adducts. Nat. Protoc. 2007, 2:2772-2781.
30. Sambrook J., Fritsch E.F., Maniatis T. Molecular Cloning: A Laboratory Manual 1989, E3-E4. Cold Spring Harbor Laboratory Press, New York. 2nd ed.
31. Phillips D.H., Castegnaro M. Standardization and validation of DNA adduct postlabelling methods: report of interlaboratory trials and production of recommended protocols. Mutagenesis 1999, 14(3):301-315.
32. Tang D., Phillips D.H., Stampfer M., Mooney L., Hsu Y., Cho Y., Tsai W.-Y., Ma J., Cole K., Ni Shé M., Perera F. Association between carcinogen-DNA adducts in white blood cells and lung cancer risk in the physicians health study. Cancer Res. 2001, 61:6708-6712.
33. Pérez-Morales R., Méndez-Ramírez I., Castro-Hernández C., Martínez-Ramírez O.C., Gonsebatt M.E., Rubio J. Polymorphisms associated with the risk of lung cancer in a healthy Mexican mestizo population: application of the additive model for cancer. Genet. Mol. Biol. 2011, 34:546-552.
34. Rundle A., Tang D., Zhou J., Cho S., Perera F. The association between glutathione S-transferase M1 genotype and polycyclic aromatic hydrocarbon-DNA adducts in breast tissue. Cancer Epidemiol. Biomarkers Prev. 2000, 9:1079-1085.
35. Gao X., Starmer J., Martin E.R. A multiple testing correction method for genetic association studies using correlated single nucleotide polymorphisms. Genet. Epidemiol. 2008, 32:361-369.
36. Randerath K., Putman K.L., Osterburg H.H., Johnson S.A., Morgan D.G., Finch C.E. Age-dependent increases of DNA adducts (I-compounds) in human and rat brain DNA. Mutat. Res. 1993, 295:11-18.
37. Ricceri F., Godschalk R.W., Peluso M., Phillips D.H., Agudo A., Georgiadis P., Loft S., Tjonneland A., Raaschou-Nielsen O., Palli D., Perera F., Vermeulen R., Taioli E., Sram R.J., Munnia A., Rosa F., Allione A., Matullo G., Vineis P. Bulky DNA adducts in white blood cells: a pooled analysis of 3600 subjects. Cancer Epidemiol. Biomarkers Prev. Dec 19 2010, 3174-3181.
38. Pratt M.M., John K., MacLean A.B., Afework S., Phillips D.H., Poirier M.C. Polycyclic aromatic hydrocarbon (PAH) exposure and DNA adduct semi-quantitation in archived human tissues. Int. J. Environ. Res. Publ. Health 2011, 8:2675-2691.
39. Palli D., Vineis P., Russo A., Berrino F., Krogh V., Masala G., Munnia A., Panico S., Taioli E., Tumino R., Garte S., Peluso M. Diet, metabolic polymorphisms and DNA adducts: the EPIC-Italy cross-sectional study. Int. J. Cancer 2000, 87:444-451.
40. Peluso M., Airoldi L., Munnia A., Colombi A., Veglia F., Autrup H., Dunning A., Garte S., Gormally E., Malaveille C., Matullo G., Overvad K., Raaschou-Nielsen O., Clavel-Chapelon F., Linseisen J., Boeing H., Trichopoulou A., Palli D., Krogh V., Tumino R., Panico S., Bueno-De-Mesquita B.H., Peeters P.H., Kumle M., Agudo A., Martinez C., Dorronsoro M., Barricarte A., Tormo M.J., Quiros J.R., Berglund G., Jarvholm B., Day N.E., Key T.J., Saracci R., Kaaks R., Riboli E., Bingham S., Vineis P. Bulky DNA adducts, 4-aminobiphenyl-haemoglobin adducts and diet in the European prospective investigation into cancer and nutrition (EPIC) prospective study. Br. J. Nutr. 2008, 100:489-495.
41. Rothman N., Poirier M.C., Baser M.E., Hansen J.A., Gentile C., Bowman E.D., Strickland P.T. Formation of polycyclic aromatic hydrocarbon-DNA adducts in peripheral white blood cells during consumption of charcoal-broiled beef. Carcinogenesis 1990, 11:1241-1243.
42. Weiserbs K.F., Jacobson J.S., Begg M.D., Wang L.W., Wang Q., Agrawal M., Norkus E.P., Young T.L., Santella R.M. A cross-sectional study of polycyclic aromatic hydrocarbon-DNA adducts and polymorphism of glutathione S-transferases among heavy smokers by race/ethnicity. Biomarkers 2003, 8:142-155.
43. Piipari R., Nurminen T., Savela K., Hirvonen A., Mantyla T., Anttila S. Glutathione S-transferases and aromatic DNA adducts in smokers bronchoalveolar macrophages. Lung Cancer 2003, 39:265-272.
44. Christmann M., Kaina B. O(6)-methylguanine-DNA methyltransferase (MGMT): impact on cancer risk in response to tobacco smoke. Mutat. Res. 2012, 736:64-74. Epub 2011 Jun 14.
45. Hecht S.S. Biochemistry, biology and carcinogenicity of tobacco-specific N-nitrosamines. Chem. Res. Toxicol. 1998, 11:560-590.
46. Randerath K., Randerath E., Agrawal H.P., Gupta R.C., Schurdak M.E., Vijayaraj R. Postlabeling methods for carcinogen-DNA adduct analysis. Environ. Health Perspect. 1985, 62:57-65.
47. 32P-postlabelling in DNA and human embryonal lung fibroblast (HEL). Carcinogenesis 1996, 17:801-808.
48. 32P-postlabeling analysis of non-radioactive aromatic carcinogen-DNA adducts. Carcinogenesis 1982, 3:1081-1092.
49. Phillips D.H., Hewer A., Grover P.L. Aromatic DNA adducts in human bone marrow and peripheral blood leukocytes. Carcinogenesis 1986, 7:2071-2075.
50. 32P-postlabeling. Int. J. Cancer 2001, 93:450-454.
51. Hoffmann D., Hoffmann I., El-Bayoumy K. The less harmful cigarette: a controversial issue-a tribute to Ernst L. Wynder. Chem. Res. Toxicol. 2001, 14:767-790.
52. Randerath K., Randerath E., Smith C.V., Chang J. Structural origins of bulky oxidative DNA adducts (type II I-compounds) as deduced by oxidation of oligonucleotides of known sequence. Chem. Res. Toxicol. 1996, 9:247-254.
53. Lloyd D.R., Phillips D.H., Carmichael P.L. Generation of putative intrastrand cross-links and strand breaks in DNA by transition metal ion-mediated oxygen radical attack. Chem. Res. Toxicol. 1997, 10:393-400.
54. Seeman I., Dixon M., Haussmann H.-J. Acetaldehyde in mainstream tobacco smoke: formation and occurrence in smoke and bioavailability in the smoker. Chem. Res. Toxicol. 2002, 15:1332-1346.
55. Arif J.M., Dresler C., Clapper M.L., Gairola C.G., Srinivasan C., Lubet R.A., Gupta R.C. Lung DNA adducts detected in human smokers are unrelated to typical polyaromatic carcinogens. Chem. Res. Toxicol. 2006, 19:295-299.
56. 6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy. DNA Repair (Amst.) 2007, 1100-1115.
57. 6-methylguanine-DNA methyltransferase, and its application for monitoring human exposure to alkylating carcinogens. Cancer Res. 1994, 54:3726-3731.
58. 6-methylguanine lesion. Mol. Cell. Biol. 1998, 8:1660-1669.
59. Mishina Y., Duguid E.M., He C. Direct reversal of DNA alkylation damage. Chem. Rev. 2006, 106:215-232.
60. Heery D.M., Kalkhoven E., Hoare S., Parker M.G. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 1997, 12:733-736.
61. Westin S., Kurokawa R., Nolte R.T., Wisely G.B., Mclnerney E.M., Rose D.W., Milburn M.V., Rosenfeld M.G., Glass C.K. Interactions controlling the assembly of nuclear receptor heterodimers and co-activators. Nature 1998, 395:199-202.
62. Flaveny C., Reen R.K., Kusnadi A., Perdew G.H. The mouse and human Ah receptor differ in recognition of LxxLL motifs. Arch. Biochem. Biophys. 2008, 471:215-223.
63. 6-methylguanine-DNA methyltransferase upon alkylation of its active site by SN1 (indirect-acting) and SN2 (direct-acting) alkylating agents: breaking a "salt-link". Biochemistry 1996, 35:12259-12266.
64. Teo A.K., Oh H.K., Ali R.B., Li B.F. The modified human DNA repair enzyme O(6)-methylguanine-DNA methyltransferase is a negative regulator of estrogen receptor-mediated transcription upon alkylation DNA damage. Mol. Cell. Biol. 2001 Oct, 21:7105-7114.